http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#Head http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#assertion http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#provenance http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#pubinfo http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#assertion http://purl.obolibrary.org/obo/DOID_11729 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_11729 http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01112 http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#association http://www.w3.org/2000/01/rdf-schema#label cefuroxime axetil tablets are a cephalosporin antibacterial drug indicated for the treatment of the following infections due to susceptible bacteria 1 pharyngitis tonsillitis adults and pediatric patients 1 1 acute bacterial otitis media pediatric patients 1 2 acute bacterial maxillary sinusitis adults and pediatric patients 1 3 acute bacterial exacerbations of chronic bronchitis adults and pediatric patients 13 years and older 1 4 uncomplicated skin and skin structure infections adults and pediatric patients 13 years and older 1 5 uncomplicated urinary tract infections adults and pediatric patients 13 years and older 1 6 uncomplicated gonorrhea adults and pediatric patients 13 years and older 1 7 early lyme disease adults and pediatric patients 13 years and older 1 8 to reduce the development of drug resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients 13 years and older with mild to moderate pharyngitis tonsillitis caused by susceptible strains of streptococcus pyogenes limitations of use the efficacy of cefuroxime axetil tablets in the prevention of rheumatic fever was not established in clinical trials the efficacy of cefuroxime axetil tablets in the treatment of penicillin resistant strains of streptococcus pyogenes cefuroxime axetil tablets are indicated for the treatment of pediatric patients who can swallow tablets whole with acute bacterial otitis media caused by susceptible strains of streptococcus pneumoniae haemophilus influenzae moraxella catarrhalis streptococcus pyogenes cefuroxime axetil tablets are indicated for the treatment of adult and pediatric patients 13 years and older with mild to moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae haemophilus influenzae limitations of use the effectiveness of cefuroxime axetil tablets for sinus infections caused by b lactamase producing haemophilus influenzae moraxella catarrhalis see clinical studies 14 1 cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with mild to moderate acute bacterial exacerbations of chronic bronchitis caused by susceptible strains b lactamase negative strains or b lactamase negative strains cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with mild to moderate acute bacterial exacerbations of chronic bronchitis caused by susceptible strains of streptococcus pneumoniae haemophilus influenzae haemophilus parainfluenzae cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with uncomplicated skin and skin structure infections caused by susceptible strains of staphylococcus aureus streptococcus pyogenes cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with uncomplicated urinary tract infections caused by susceptible strains of escherichia coli klebsiella pneumoniae cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with uncomplicated gonorrhea urethral and endocervical caused by penicillinase producing and non penicillinase producing susceptible strains of neisseria gonorrhoeae neisseria gonorrhoeae cefuroxime axetil tablets are indicated for the treatment of adult patients and pediatric patients aged 13 and older with early lyme disease erythema migrans caused by susceptible strains of borrelia burgdorferi to reduce the development of drug resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria when culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy in the absence of such data local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01112 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#provenance http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#pubinfo http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#sig http://purl.org/nanopub/x/hasSignature YoZdVeHAqFFjcAhQ26iLcMifj0YEkw/AcWBoQv3AEeV5td0ZKkLiAy/w+5rfuXEEXImX6tF4muA7QY9WncsSkDo7pYm/0bDJSe5AMpwZoH6Fz2GryEYzMDcCNAzR6PNlYJTDCH+jr84jxXTyyR+xcxqYnz2FdVtWbgLVd9f5j7c= http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI http://purl.org/dc/terms/created 2021-06-21T10:38:09.097+02:00 http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RARzLy7JCghoOK1toyj4zkq2wqV90SiHIeeDEm2V0IKcI https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs